

Original Research Article

River State, Nigeria COVID-19 Statistics between April 2020 and March 2021: Demographics, geographic spread, and commonly presented symptoms

ABSTRACT

Aims: This research provides a preliminary epidemiological study of the COVID-19 outbreak in Rivers State, Nigeria.

Study design: Retrieval of secondary data

Place and Duration of Study: The Epidemiology Department of the Rivers State Department of Public Health, Ministry of Health in December 2022..

Methodology: All patients with incomplete data were excluded from the study. Secondary data recorded in Excel was retrieved from the epidemiology Department of the Rivers State Ministry of Health and exported to IBM Statistical Product and Service Solutions (SPSS) version 25 for analysis. Frequencies were generated and reported as tables. Ethical approval was obtained from the Ethics Committee of the State Ministry of Health Board, Port Harcourt.

Results: 10.5% of data were incomplete. Mortality rate was 1.4%. About two-thirds of those infected were in Port Harcourt Local Government Area (LGA) with almost one-third in Obio/Akpor LGA. 17.4% of those infected had a positive history of travel and 1% attended burial before the onset of infection. Four [4843 (76.9%)] out of every five people that were confirmed presented with symptoms that ranged from fever, cough, loss of smell, and chest pain among others. There was a statistical correlation between the sex and age group of those infected (<0.0001). More males were infected than females and those of age groups 31-40, 41-50. constituted three-fifths of those infected.

Conclusion: Males were three times more infected than females and the mortality rate was 1.4%.

Keywords: Common symptoms, COVID-19, Demographics, Geographic spread

1. INTRODUCTION

The World Health Organization (WHO) declared the novel coronavirus outbreak in Wuhan, China, a global emergency on January 20, 2020.¹ They acknowledged its potential to cause a pandemic worldwide on February 24, 2020, and declared the COVID-19 pandemic on March 11, 2020.¹ From a scientific standpoint, rarely has a single pathology required the mobilization of so much effort and resources as COVID-19.² Globally, as of January 9, 2023, 20.5 million cases of COVID-19 had been confirmed worldwide, and 182,000 deaths were reported to the World Health Organization.¹ In addition, a total of 5.51 billion people worldwide have had a dose of a COVID-19 vaccine (71.8% of the world population).^{3,4} In Africa as of January 9, 2023, there were 12, 216,748 confirmed cases, 256,542 deaths, and 801 million vaccine doses were administered with 25.6% of Africans fully vaccinated.^{2,4-6} The COVID-19 infection was first reported in Nigeria on February 27, 2020 and as of January 9, 2023, there were 266,463 confirmed cases, 3155 deaths and 28.1% of the population fully vaccinated. 4,7 -11

By April 21, 2020, the race to develop the COVID-19 vaccine started and by May 10, 2022, more than 5.16 billion (67.2%) people worldwide have been reported to have received at least a dose of the COVID-19 vaccine.¹² By that time in

Nigeria, less than 35% of the population had taken at least one dose of the COVID-19 vaccine and only 7.4% had been fully vaccinated.¹²

Despite the devastating effects of the COVID-19 pandemic on many countries all over the world, the impact in some parts of Africa was less.^{2,13} The pandemic effects in the African continent, Nigeria inclusive, had not been as devastating as in other continents despite the prediction that it would be the most vulnerable and worst affected continent.¹³⁻¹⁷ Thus, many public health experts were puzzled because Africa reported fewer cases and deaths from COVID-19 than predicted.¹³ Furthermore, most of the identified cases of COVID-19 in Africa were imported from Europe and the United States, rather than from the original COVID-19 epicenter China.¹⁸

Since the rapidly evolving COVID-19 pandemic placed a heavy burden on healthcare systems, it was projected that the pandemic would be worse in low- and- middle-income countries (LMICs) because of weak healthcare systems, scarce financial resources, inadequate protective equipment, poor testing and treatment capacities, and lack of research funding.¹⁹ However, this was not been the case as the mortality rate was low in the LMICs.

There is a paucity of data in South-South on the pattern and presentation of COVID-19 cases in Rivers State. Moreso, what is the demographic of those infected in the community, where was the disease concentrated and how did it present? This study answered these questions

2. MATERIAL AND METHODS / EXPERIMENTAL DETAILS / METHODOLOGY

This study is a report of the COVID-19 cases during the peak period (April 2020 to March 2021) of the pandemic in Rivers State, Nigeria. The secondary data was retrieved from the Epidemiology Department of the Rivers State Department of Public Health, Ministry of Health in December 2022.

Data was entered on Microsoft Excel 2010 (Microsoft Corp, Washington, USA) and analyzed with the Statistical Product and Service Solutions (SPSS) version 25 (IBM, Armonk, New York, USA). Descriptive statistics such as frequencies, percentages, means, and standard deviations were used to summarize the data. The association between participants' characteristics was analyzed using the chi-square test. Results were presented in tables.

The inclusion criteria were the complete secondary data of those identified, diagnosed, monitored, and managed for COVID-19 between April 2020 to March 2021 while the exclusion criteria were incomplete data.

The ethical approval was obtained from the Rivers State Ministry of Health Board's Ethics Committee and the University of Port Harcourt Ethics Committee.

3. RESULTS AND DISCUSSION

Table 1 shows the demographics of the patients who had COVID-19 in Rivers State.

Of the seven thousand and thirty-eight data (7083) patients, only six thousand, two hundred and ninety-nine (6299) had complete data. More males were infected than females with a M: F of 3:1. 57% of those infected were in the fifth and sixth age group and 70.8% had at least a post-secondary education. Three-fifths were diagnosed at home and 85.8% were diagnosed at the Rivers State University Teaching Hospital (RSUTH) COVID-19 center. COVID-19 mortality in Rivers State was 1.4%.

Table 1. Demographics of those infected with COVID-19 between April 2020 to March

2021

Variables	Frequency	Percentage
------------------	------------------	-------------------

Gender		
Male	4817	76.5
Female	1482	23.5
Age group		
1-10	96	1.5
11-20	515	8.2
21-30	907	14.4
31-40	2060	32.7
41-50	1655	26.3
51-60	738	11.7
61-70	237	3.8
71-80	68	1.1
81-90	21	0.3
>90	2	0.0
Education		
No formal	1296	20.6
Nursery	18	0.3
Primary	289	4.6
Secondary	236	3.7
Post-secondary	3330	52.9
Tertiary	1130	17.9
Diagnostic Centers		
Rivers State University Teaching Hospital (RSUTH)	964	13.9
The University of Port Harcourt Teaching Hospital (UPTH)	344	4.9
Other health facilities	1575	22.7
Home	4070	58.5
Hospitalization		
Yes	1395	22.1
No	4904	77.9

Laboratory centers

Rivers State University Teaching Hospital (RSUTH)	5403	85.8
The University of Port Harcourt Teaching Hospital (UPTH)	424	6.7
SPDC Molecular lab	218	3.5
INDORAMA Molecular lab	83	1.3
Other government-approved labs	171	2.7

Mortality

Alive	6211	98.6
Dead	88	1.4
Total	6299	100.0

Mean age= 38.63±13.37 years, Median = 38 years, SEM = 0.17, V = 178.67

Table 2 shows that 1 out of 3 men who were infected were in the 31-40 age group and 3 out of 10 men were in the 41-50 age group, while for women, 1 out of 5 and 1 out of 4 women who were infected were in the 21-30 and 31-40 age groups respectively. The association between age and sex was statistically significant.

Table 2. Association between sex and age group of all infected with COVID-19
between April 2020 and March 2021

Variables	Frequency	Percentage	Frequency	Percentage	Frequency	Percentage	<i>P</i>
Sex	Male		Female		Total		
Age groups (years)							<0.001
1-10	57	1.2	39	2.6	96	1.5	
11-20	267	5.5	248	16.7	515	8.2	
21-30	604	12.5	303	20.5	907	14.4	
31-40	1675	34.8	385	25.9	2060	32.7	
41-50	1412	29.3	243	16.4	1655	26.3	
51-60	578	12.0	160	10.8	738	11.7	
61-70	171	3.6	66	4.5	237	3.8	
71-80	42	0.9	26	1.8	68	1.1	
81-90	11	0.2	10	0.7	21	0.3	

>90	0	0.0	2	0.1	2	0.0
Total	4817	100.0	1482	100.0	6299	100.0

Table 3 shows that most of those infected with COVID-19 dwelled in the urban LGAs of Rivers State.

Table 3. Geographic spread of those infected with COVID-19 between April 2020 to

March 2021

Variables	Frequency	Percentage
Geographic Spread by LGAs		
Obio/Akpor	1888	30.0
Port Harcourt	3998	63.5
Eleme	258	4.1
Bonny	80	1.3
Ikwerre	12	0.2
Oyigbo	12	0.2
Others	51	0.8
Total	6299	100.0

Table 4 shows some of the symptoms presented by those infected. 76.9% of the patients presented with at least one sign/symptom. One-fifth presented with dry cough, a tenth with fever, and a third with dysphagia, bleeding gum, malaise, and anorexia. 6% had amsonia.

Table 4. Some signs and symptoms presented by those infected with COVID-19

between April 2020 to March 2021

Variables	Frequency	Percentage
Symptoms		
Yes	4843	76.9
Abdominal symptoms		
Yes	6	0.1

Dysphagia		
Yes	1976	31.4
Chest pain		
Yes	73	1.2
Chills/Sweats		
Yes	11	0.2
Confusion		
Yes	3	0.0
Dry cough		
Yes	1289	20.5
Cough + sputum		
Yes	391	6.2
Cough+ blood		
Yes	46	0.7
Fever		
Yes	604	9.6
Headache		
Yes	270	4.3
Bleeding gum		
Yes	1976	31.4
Joint pain		
Yes	7	0.1
Lung fluid (auscultation and x-rays)		
Yes	5	0.1
Malaise		
Yes	1976	31.4
Stiff neck		
Yes	61	1.0
Hematemesis		

Yes	77	1.2
Loss of appetite		
Yes	1976	31.4
Vomiting		
Yes	39	0.6
Conjunctivitis		
Yes	5	0.1
Acute respiratory syndrome		
Yes	16	0.3
Loss of taste		
Yes	5	0.1
Loss of smell		
Yes	378	6.0
Enlarged lymph nodes		
Yes	47	0.7
Wheezing		
Yes	37	0.6
Inability to walk		
Yes	36	0.6
Flail Chest		
Yes	36	0.6
Oxygen saturation less than 94		
Yes	1978	31.4
Total	6229	100.0

Discussion

It has been said that pandemics are not gender-neutral.²⁰⁻²³ The demographics of those infected with COVID-19 changed as the pandemic progressed. There was a shift from the older age group to the younger ones. A study done in the United Kingdom reported an increase in excess hospital admissions since Aug 1, 2020, among women aged 20–40 years old.²⁴

Of the female patients admitted to the hospital, 49 (12.0%) were aged 21–30 years, versus 33 (8.1%) aged 41–50 years, and 35 (8.6%) aged 61–69 years. Of males admitted to the hospital, only 17 (3.7%) were in the 21–30 years age bracket.²⁴ Studies have shown that severe disease and mortality have been overall greater among males, aged>60.²⁵ The one-year report of those infected with COVID-19 in Rivers State, Nigeria showed that of the women who were infected, 303 (20.5%) were aged 21–30 years, versus 243 (16.4%) aged 41–50 years, and 66 (4.5%) aged 61–70 years. As regards the males who were infected, 604 (12.5%) were in the 21–30 years age bracket.

The Rivers State COVID-19 report showed a mean age of 38.63 ± 13.37 and that males were 3 times more infected than females. This could be attributed to the fact that many men are breadwinners and move around a lot, have lower rates of hand washing, and have underlying conditions.²⁶ This can also be due to the biological differences between the 2 sexes, as studies have shown that women have stronger immune systems than males.²⁷ Studies done in other parts of the world also reported male dominance.²⁸⁻³² A study that reported COVID data in 10 European countries observed that women diagnosed with COVID-19 outnumbered men while considering people of working age with a reversal in pattern around retirement.³³ It further reported that the infection rates of women in the age group 60-69 reduced and resulted in a cross-over with infection rates among men. Furthermore, the relative disadvantage of women peaked at ages 20-29, while those of men peaked at ages 70-79.³⁴ The elevated infection rates among women of working age were attributed to the likelihood of their higher share in health- and care-related occupations in prime working ages.³⁵ The same factors that determine women's higher life expectancy account for their lower fatality and higher male disadvantage at older ages.³³

Just like in other countries, most of those infected came from urban areas. COVID-19 started in the urban communities before spreading to the rural areas.³⁴ This can be attributed to their lifestyles and wealth. Many can afford to travel to other countries and in fact, some were trapped in those countries during the pandemic.^{35,36} Also, urban areas are high-density areas with many recreation centers and clubs.³⁷ Thus, the ease of spread was rapid among them.

The Rivers State Covid data showed that 31.4% of those infected presented with a sore throat, bleeding gum, malaise, and loss of appetite. 9.6% presented with a fever. The commonest symptom presented in the state was sore throat. This compares to the study done in China by Guan et al that reported the same.³⁸ Other studies reported varying types of symptoms. A study done among 41 patients in China reported that 98% and 76% had fever and cough respectively.³⁹ Another study reported 26% fever and 17.4% sore throat among the participants.⁴⁰ Jin-jin Zhang et al reported 91.7% fever and 75% cough among participants.⁴¹

4. CONCLUSION

Males were three times more infected than females and the COVID-19 mortality rate within the reported one year was 1.4%.

CONSENT (WHEREEVER APPLICABLE)

"All authors declare that 'written informed consent was obtained from the patient (or other approved parties) for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal."

ETHICAL APPROVAL (WHEREEVER APPLICABLE)

University of Port Harcourt and Rivers State Rivers State Ministry of Health Board's Ethics Committees.

REFERENCES

1. Covid WHO. Dashboard. Geneva: World Health Organization 2020 @ <https://covid19.who.int>. Assessed 22 December 2023.
2. Lone SA, Ahmad A. COVID-19 pandemic—an African perspective. *Emerging microbes and infections*. 2020; 9(1):1300-1308.
3. Mohd HA, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir. *Virology journal*. 2016; 13:1-7
4. Shrotri M, Swinnen T, Kampmann B, Parker EP. An interactive website tracking COVID-19 vaccine development. *The Lancet Global Health*. 2021; 9(5): e590-2.
5. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AE, Nkengasong JN. COVID-19 in Africa: the spread and response. *Nature Medicine*. 2020; 26(7):999-1003.
6. Tessema SK, Nkengasong JN. Understanding COVID-19 in Africa. *Nature Reviews Immunology*. 2021; 21(8):469-470.
7. Garba B, Zakaria Z, Salihu MD, Bande F, Saidu B, Bala JA. Breaking the cycle of the COVID-19 transmission: A challenge for Nigeria. *Journal of Global Health*. 2020; 10(2).
8. Muhammad DG, Ahmad HY, Umar R. *JAT XML*. *Women health*.2021; 3:37-55.
9. Ogundokun RO, Lukman AF, Kibria GB, Awotunde JB, Aladeitan BB. Predictive modelling of COVID-19 confirmed cases in Nigeria. *Infectious Disease Modelling*. 2020; 5:543-8.
10. Odunayo BJ. On the monitoring of coronavirus disease 2019 (covid-19) pandemic outbreak in Nigeria. *African Journal of Biology and Medical Research*. 2020;3(2):33-40.
11. Mathieu E, Ritchie H, Rodés-Guirao L, Appel C, Giattino C, Hasell J, et al. Coronavirus pandemic (COVID-19). *Our world in data*. 2020 Mar 5.
12. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M, et al. An overview of COVID-19. *Journal of Zhejiang University. Science. B*. 2020 May;21(5):343.
13. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. *Science*. 2021; 371(6524):27-28.
14. Kavanagh MM, Erondun NA, Tomori O, Dzau VJ, Okiro EA, Maleche A, et al. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. *The Lancet*. 2020; 395(10238):1735-1738.

15. Massinga Loembé M, Tshangela A, Salyer SJ, Varma JK, Ouma AE, Nkengasong JN. COVID-19 in Africa: the spread and response. *Nature Medicine*. 2020 Jul;26(7):999-1003.
16. Moore M, Gelfeld B, Okunogbe A, Paul C. Identifying future disease hot spots: infectious disease vulnerability index. *Rand health quarterly*. 2017; 6(3).
17. Njenga MK, Dawa J, Nanyingi M, Gachohi J, Ngere I, Letko M, et al. Why is there low morbidity and mortality of COVID-19 in Africa? *The American journal of tropical medicine and hygiene*. 2020;103(2):564.
18. Adegboye OA, Adekunle AI, Pak A, Gayawan E, Leung DH, Rojas DP, et al. Change in outbreak epicenter and its impact on the importation risks of COVID-19 progression: A modeling study. *Travel Medicine and Infectious Disease*. 2021; 40:101988.
19. Betsch C, Wieler LH, Habersaat K. Monitoring behavioral insights related to COVID- The Lancet. 2020; 395(10232):1255-6.
20. Campisi T, Basbas S, Skoufas A, Kaltsidis A, Tesoriere G. The impact of COVID-19 is not gender neutral: regional scale changes in modal choices in Sicily. *Transportation Research Procedia*. 2023; 69:584-91.
21. Koontalay A, Suksatan W, Prabsangob K, Sadang JM. Healthcare workers' burdens during the COVID-19 pandemic: A qualitative systematic review. *Journal of Multidisciplinary Healthcare*. 2021; 3015-25.
22. Simba H, Ngcobo S. Are pandemics gender neutral? Women's health and COVID-19. *Frontiers in Global Women's Health*. 2020; 1:570666.
23. Morgan R, Davies SE, Feng H, Gan CC, Grépin KA, Harman S, et al. Using gender analysis matrixes to integrate a gender lens into infectious diseases outbreaks research. *Health policy and planning*. 2022; 37(7):935-41.
24. Venkatesan P. The changing demographics of COVID-19. *The Lancet Respiratory Medicine*. 2020; 8(12): e95.
25. Sobotka T, Brzozowska Z, Muttarak R, Zeman K, Di Lego V. Age, gender and COVID-19 infections. *MedRxiv*. 2020: 2020-05.
26. Betron M, Gottert A, Pulerwitz J, Shattuck D, Stevanovic-Fenn N. Men and COVID-19: Adding a gender lens. *Global Public Health*. 2020; 15(7):1090-2.
27. Khan AR, Ratele K. Men and Covid-19: Explicating the need for masculinity analysis. *Journal of Community Positive Practices*. 2021; 1(1):3-7.
28. Mukherjee S, Pahan K. Is COVID-19 gender-sensitive? *Journal of Neuroimmune Pharmacology*. 2021; 16:38-47.
29. Ambrosino I, Barbagelata E, Ortona E, Ruggieri A, Massiah G, Giannico OV, et al. Gender differences in patients with COVID-19: a narrative review. *Monaldi Arch Chest Dis* 2020; 90(2).
30. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differ* 2020; 11:29
31. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. *Front Public Health* 2020; 8:152
32. Team TNCPERE. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19). *China CDC Weekly* 2020; 2:113–122
33. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. *Allergy*. 2020;75(7):1730-41.
34. Cuadros DF, Branscum AJ, Mukandavire Z, Miller FD, MacKinnon N. Dynamics of the COVID-19 epidemic in urban and rural areas in the United States. *Annals of epidemiology*. 2021; 59:16-20.

35. Huang Q, Jackson S, Derakhshan S, Lee L, Pham E, Jackson A, et al. Urban-rural differences in COVID-19 exposures and outcomes in the South: A preliminary analysis of South Carolina. *PloS one*. 2021;16(2): e0246548.
36. Gupta D, Biswas D, Kabiraj P. COVID-19 outbreak and Urban dynamics: Regional variations in India. *GeoJournal*. 2022; 87(4):2719-37.
37. Acuto M. COVID-19: Lessons for an Urban (izing) World. *One Earth*. 2020; 2(4):317-9.
38. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. *New England journal of medicine*. 2020; 382(18):1708-20.
39. Mehta AA, Haridas N, Belgundi P, Jose WM. A systematic review of clinical and laboratory parameters associated with increased severity among COVID-19 patients. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2021; 15(2):535-41.
40. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Yet, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*. 2020; 395(10223):497-506.
41. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *jama*. 2020; 323(11):1061-9.

UNDER PEER REVIEW